Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community About Phexxi®, a Non-hormonal Contraception Option for Women With Cancer
The collaboration will provide resources on Phexxi® vaginal contraceptive gel to oncologists, pharmacists and associated care providers.
SAN DIEGO, February 4, 2021 / PRNewswire / – Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a leading educational platform for community and academic oncology practices nationwide, launch a collaboration to have a positive impact on the quality of life of cancer patients fighting and recovering from cancer by raising awareness of the importance and availability of a new non-hormonal contraceptive method, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Evofem and NCODA will work together to develop and share educational resources and information for the Medically Integrated Oncology Pharmacy team to help their cancer patients decide which contraceptive option best meets each woman’s individual and unique needs. The collaboration starts today – World Cancer Day.
Each year in the United States, more than 800,000 new cases of cancer are reported in women.1 Many cancer treatment protocols require that patients of childbearing potential use birth control during treatment. Until the introduction of Phexxi in September 2020, prescription non-hormonal contraceptive options were extremely limited; Previously, women were generally referred to condoms or the copper IUD, a prescription medical device implanted in the uterus where it releases copper ions and causes inflammation.
“Women who are or have previously been treated for hormone-sensitive cancers should not use hormonal contraceptives as this could stimulate tumor cell growth,” said Gury Doshi, MD, Texas Oncology. “Non-hormonal contraception is the best option for these women, and it is important that each woman and her healthcare team assess and determine which of two hormone-free prescription contraceptives available, a surgically implanted device, or on-demand vaginal pH. modulator, is the best for her. “
“As a stage III breast cancer survivor, this collaboration with NCODA is extremely important to me and to the entire Evofem team,” said Saundra Pelletier, CEO of Evofem Biosciences. “I understand first-hand the extraordinary suffering – physical, mental, psychological and sexual – that women face during and after cancer treatment. We look forward to working with NCODA to support cancer patients in ensuring that this is so. that they and their oncology teams, including doctors, nurses, pharmacists and other healthcare providers are aware that there is now, finally, an FDA-approved, non-invasive, hormone-free contraceptive: Phexxi . “
“Our passion is for patients. Supporting the coordination and continuity of care while having a positive impact on the clinical results and the quality of life of cancer patients is essential to our mission. Evofem has developed an innovation that will benefit cancer patients during and long after their treatment. We look forward to raising awareness that we are confident this will be a welcome addition to their treatment plan of care, ”states Michael J. Reff, Founder and Executive Director of NCODA.
NCODA will develop a Positive Quality Intervention (PQI) in connection with Phexxi. PQIs are part of the NCODA quality standards. These resources are designed to operationalize and standardize practices to achieve positive patient outcomes. The resource will educate oncologists and other members of the medically integrated oncology pharmacy team who are involved in the care of oncology patients who may be prescribed Phexxi.
Phexxi is the first and only FDA approved non-hormonal contraceptive vaginal gel. It is designed to be used immediately before or up to an hour before intercourse. It was approved in May 2020 and is now available in the United States by prescription.
Phexxi works to maintain vaginal pH, which reduces sperm motility, reducing the risk of sperm reaching the egg, and is the first non-hormonal contraceptive method created for women in decades.
The National Community Oncology Dispensing Association (NCODA) seeks to empower the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. NCODA addresses the growing need for MIP cancer clinics to improve pharmacy-level operations to deliver enduring quality and value to all stakeholders involved in the care of cancer patients receiving oral therapy. NCODA adds value to practices through the adoption of quality standards, the sharing of best practices and the improvement of financial sustainability. For more information on NCODA, visit www.ncoda.org.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company engaged in the development and commercialization of innovative products to address the unmet sexual and reproductive health needs of women, including hormone-free contraception. controlled by the woman and protection against certain transmitted infections (STIs). The company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company’s lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing phase 3 clinical trial, ‘EVOGUARD“. For more information, please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Phexxi® is an on-demand birth control method used to prevent pregnancy. Phexxi® is not effective when used after intercourse.
IMPORTANT SAFETY INFORMATION
If you have a history of repeated UTIs or other urinary tract problems, avoid Phexxi®.
The most common side effects were vaginal burning, vaginal itching, yeast infection, urinary tract infections, vaginal area discomfort, bacterial vaginosis, vaginal discharge, genital discomfort (including partner male) and pain when urinating.
Phexxi® does not protect against sexually transmitted infections, including HIV.
Contact your health care provider if you experience severe genital irritation or discomfort or urinary tract symptoms.
For more information about Phexxi®, talk to your healthcare professional and view full product information.
Please report side effects by contacting Evofem Biosciences® toll free at 1-833-EVFMBIO or by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This press release includes “forward-looking statements” within the meaning of the safe harbor for forward-looking statements under Section 21E of the Securities Exchange Act of 1934, as amended; and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current. only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors which could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or which could adversely affect the value of Evofem Biosciences assets and businesses, are disclosed in documents filed by Evofem with of the SEC, including its annual report on Form 10. -K for the year ended December 31, 2019 filed with the SEC on March 12, 2020, its current report on Form 8-K filed with the SEC on June 2, 2020, and its quarterly report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC on November 9, 2020. All forward-looking statements are expressly qualified in their entirety by these factors. Evofem assumes no obligation to update forward-looking statements, except as required by law.
US Cancer Statistics: 2017 Incidence Highlights. US Cancer Statistics Summary, No. 17, June 2020. https://www.cdc.gov/cancer/uscs/about/data-briefs/no17-USCS-highlights-2017-incidence.htm
Investor Relations Contact
Evofem Biosciences, Inc.
Mobile phone: (917) 673-5775
Capwell Communications, Inc.
Mobile: (704) 806-5119
Show original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-and-ncoda-announce-collaboration-to-educate-oncology-community-about-phexxi-a-non-hormonal-birth-control-option- for-women-with-cancer-301221728.html
SOURCE Evofem Biosciences, Inc.